Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Ruff

Showing results (191-200 of 224) with videos related to

Pageof 23
Sort By:
American Heart Journal|February 8, 2019
Stroke prevention in atrial fibrillation: Closing the gapSean D Pokorney, Bernard J Gersh, Azhar Ahmad, et al.
The New England Journal of Medicine|November 21, 2013
Edoxaban versus warfarin in patients with atrial fibrillationRobert P Giugliano, Christian T Ruff, Eugene Braunwald, et al.
Circulation|March 19, 2019
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial InfarctionRemo H M Furtado, Marc P Bonaca, Itamar Raz, et al.
European Heart Journal|August 18, 2022
A polygenic risk score predicts atrial fibrillation in cardiovascular diseaseNicholas A Marston, Amanda C Garfinkel, Frederick K Kamanu, et al.
Circulation. Genomic and Precision Medicine|January 12, 2021
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic DiseaseNicholas A Marston, Giorgio E M Melloni, Yared Gurmu, et al.
American Journal of Preventive Cardiology|July 6, 2026
Use of a polygenic risk score to enhance early detection of coronary atherosclerosisMilena Petranović, Yi-Pin Lai, Daniel Huck, et al.
The New England Journal of Medicine|November 13, 2018
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.
Circulation|March 19, 2019
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes MellitusEri T Kato, Michael G Silverman, Ofri Mosenzon, et al.
American Heart Journal|August 30, 2024
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and designSneha S Jain, Kenneth W Mahaffey, Karen S Pieper, et al.
Journal of the American College of Cardiology|August 27, 2025
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular RiskPaul M Haller, Giorgio E M Melloni, David D Berg, et al.
Pageof 23

Showing results (191-200 of 224) with videos related to

Sort By:
Pageof 23
American Heart Journal|February 8, 2019
Stroke prevention in atrial fibrillation: Closing the gapSean D Pokorney, Bernard J Gersh, Azhar Ahmad, et al.
The New England Journal of Medicine|November 21, 2013
Edoxaban versus warfarin in patients with atrial fibrillationRobert P Giugliano, Christian T Ruff, Eugene Braunwald, et al.
Circulation|March 19, 2019
Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial InfarctionRemo H M Furtado, Marc P Bonaca, Itamar Raz, et al.
European Heart Journal|August 18, 2022
A polygenic risk score predicts atrial fibrillation in cardiovascular diseaseNicholas A Marston, Amanda C Garfinkel, Frederick K Kamanu, et al.
Circulation. Genomic and Precision Medicine|January 12, 2021
Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic DiseaseNicholas A Marston, Giorgio E M Melloni, Yared Gurmu, et al.
American Journal of Preventive Cardiology|July 6, 2026
Use of a polygenic risk score to enhance early detection of coronary atherosclerosisMilena Petranović, Yi-Pin Lai, Daniel Huck, et al.
The New England Journal of Medicine|November 13, 2018
Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D Wiviott, Itamar Raz, Marc P Bonaca, et al.
Circulation|March 19, 2019
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes MellitusEri T Kato, Michael G Silverman, Ofri Mosenzon, et al.
American Heart Journal|August 30, 2024
Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and designSneha S Jain, Kenneth W Mahaffey, Karen S Pieper, et al.
Journal of the American College of Cardiology|August 27, 2025
A Polygenic Risk Score to Predict Incident Heart Failure Across the Spectrum of Cardiovascular RiskPaul M Haller, Giorgio E M Melloni, David D Berg, et al.
Pageof 23